FR2775187B1 - Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo - Google Patents
Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivoInfo
- Publication number
- FR2775187B1 FR2775187B1 FR9901903A FR9901903A FR2775187B1 FR 2775187 B1 FR2775187 B1 FR 2775187B1 FR 9901903 A FR9901903 A FR 9901903A FR 9901903 A FR9901903 A FR 9901903A FR 2775187 B1 FR2775187 B1 FR 2775187B1
- Authority
- FR
- France
- Prior art keywords
- epothilone
- antiproliferative
- manufacture
- composition
- pharmaceutical preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9803907.6A GB9803907D0 (en) | 1998-02-25 | 1998-02-25 | Organic compounds |
GBGB9803905.0A GB9803905D0 (en) | 1998-02-25 | 1998-02-25 | Organic compounds |
GBGB9805937.1A GB9805937D0 (en) | 1998-03-19 | 1998-03-19 | Organic compounds |
GBGB9805936.3A GB9805936D0 (en) | 1998-03-19 | 1998-03-19 | Organic compounds |
US09/233,993 US6302838B1 (en) | 1998-02-25 | 1999-01-19 | Cancer treatment with epothilones |
Publications (2)
Publication Number | Publication Date |
---|---|
FR2775187A1 FR2775187A1 (fr) | 1999-08-27 |
FR2775187B1 true FR2775187B1 (fr) | 2003-02-21 |
Family
ID=27517450
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR9901903A Expired - Fee Related FR2775187B1 (fr) | 1998-02-25 | 1999-02-16 | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
Country Status (10)
Country | Link |
---|---|
US (4) | US6635666B2 (fr) |
EP (1) | EP1056453B1 (fr) |
JP (1) | JP2002504511A (fr) |
AU (1) | AU755944B2 (fr) |
BE (1) | BE1011980A5 (fr) |
CA (1) | CA2319752A1 (fr) |
FR (1) | FR2775187B1 (fr) |
IT (1) | ITMI990375A1 (fr) |
NZ (1) | NZ506187A (fr) |
WO (1) | WO1999043320A1 (fr) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE59610943D1 (de) | 1995-11-17 | 2004-04-22 | Biotechnolog Forschung Gmbh | Epothilon-Derivate, ihre Herstellung und Verwendung |
JP4274583B2 (ja) | 1996-11-18 | 2009-06-10 | ゲゼルシャフト・フュア・ビオテクノロギッシェ・フォルシュンク・ミット・ベシュレンクテル・ハフツング(ゲー・ベー・エフ) | エポチロンc,d,e及びf、製造と薬剤 |
US6204388B1 (en) * | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
EP0977563B1 (fr) * | 1996-12-03 | 2005-10-12 | Sloan-Kettering Institute For Cancer Research | Synthese d'epothilones, intermediaires utilises dans leur synthese, analogues et utilisations de celles-ci |
US6867305B2 (en) | 1996-12-03 | 2005-03-15 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
US6365749B1 (en) | 1997-12-04 | 2002-04-02 | Bristol-Myers Squibb Company | Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
FR2775187B1 (fr) * | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
US6498257B1 (en) | 1998-04-21 | 2002-12-24 | Bristol-Myers Squibb Company | 2,3-olefinic epothilone derivatives |
US6399638B1 (en) | 1998-04-21 | 2002-06-04 | Bristol-Myers Squibb Company | 12,13-modified epothilone derivatives |
US6303342B1 (en) | 1998-11-20 | 2001-10-16 | Kason Biosciences, Inc. | Recombinant methods and materials for producing epothilones C and D |
US6410301B1 (en) | 1998-11-20 | 2002-06-25 | Kosan Biosciences, Inc. | Myxococcus host cells for the production of epothilones |
US20020058286A1 (en) * | 1999-02-24 | 2002-05-16 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto and analogues thereof |
WO2000050022A2 (fr) * | 1999-02-26 | 2000-08-31 | Napro Biotherapeutics, Inc. | Regime de traitement pour les cancers hormonodependants |
EP1154779A2 (fr) * | 1999-02-26 | 2001-11-21 | Napro Biotherapeutics, Inc. | Regime de traitement du cancer de la prostate |
US20050042275A1 (en) * | 1999-08-04 | 2005-02-24 | Jean-Claude Sonntag | Epothilone compositions |
US6414015B1 (en) | 2000-01-28 | 2002-07-02 | Utah State University | Laulimalide microtubule stabilizing agents |
US6518421B1 (en) | 2000-03-20 | 2003-02-11 | Bristol-Myers Squibb Company | Process for the preparation of epothilone analogs |
US6593115B2 (en) | 2000-03-24 | 2003-07-15 | Bristol-Myers Squibb Co. | Preparation of epothilone intermediates |
UA75365C2 (en) * | 2000-08-16 | 2006-04-17 | Bristol Myers Squibb Co | Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon |
CN100341505C (zh) | 2001-01-25 | 2007-10-10 | 布里斯托尔-迈尔斯斯奎布公司 | 用于治疗癌症的埃博霉素类似物的给药方法 |
WO2002058699A1 (fr) * | 2001-01-25 | 2002-08-01 | Bristol-Myers Squibb Company | Formes pharmaceutiques d'epothilones pour administration orale |
AU2002245296B2 (en) * | 2001-01-25 | 2006-12-21 | Bristol-Myers Squibb Company | Methods of administering epothilone analogs for the treatment of cancer |
WO2002062338A1 (fr) * | 2001-01-25 | 2002-08-15 | Bristol-Myers Squibb Company | Formulations parenterales contenant des analogues d'epothilone |
WO2002066033A1 (fr) | 2001-02-20 | 2002-08-29 | Bristol-Myers Squibb Company | Derives d'epothilone destines au traitement de tumeurs refractaires |
JP2004522774A (ja) | 2001-02-20 | 2004-07-29 | ブリストル−マイヤーズ スクイブ カンパニー | エポチロン誘導体を用いる耐性腫瘍の治療 |
IL157443A0 (en) | 2001-03-14 | 2004-03-28 | Bristol Myers Squibb Co | Pharmaceutical compositions for the treatment of cancer including an epothilone analog and a chemotherapeutic agent |
CA2449077A1 (fr) | 2001-06-01 | 2002-12-12 | Gregory D. Vite | Derives d'epothilone |
TWI315982B (en) * | 2001-07-19 | 2009-10-21 | Novartis Ag | Combinations comprising epothilones and pharmaceutical uses thereof |
AU2008203233B2 (en) * | 2001-07-19 | 2010-04-29 | Novartis Ag | Combinations comprising epothilones and pharmaceutical uses thereof |
TW200408407A (en) * | 2001-11-30 | 2004-06-01 | Dana Farber Cancer Inst Inc | Methods and compositions for modulating the immune system and uses thereof |
TWI287986B (en) * | 2001-12-13 | 2007-10-11 | Novartis Ag | Use of Epothilones for the treatment of the carcinoid syndrome |
JP5384777B2 (ja) * | 2001-12-18 | 2014-01-08 | 有限会社大長企画 | 強筋肉剤、抗炎症剤 |
MXPA04006822A (es) | 2002-01-14 | 2004-12-08 | Novartis Ag | Combinaciones que comprenden epotilonas y anti-metabolitos. |
EP1340498A1 (fr) * | 2002-03-01 | 2003-09-03 | Schering Aktiengesellschaft | Utilisation d'épothilones dans le traitement de maladies du cerveau associées aux processus de prolifération |
US7211593B2 (en) | 2002-03-12 | 2007-05-01 | Bristol-Myers Squibb Co. | C12-cyano epothilone derivatives |
TW200403994A (en) | 2002-04-04 | 2004-03-16 | Bristol Myers Squibb Co | Oral administration of EPOTHILONES |
DE10217254A1 (de) * | 2002-04-15 | 2003-10-23 | Proteosys Ag | Verwendung von Substanzen zur Behandlung von Tumoren |
TW200400191A (en) | 2002-05-15 | 2004-01-01 | Bristol Myers Squibb Co | Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives |
US7008936B2 (en) | 2002-06-14 | 2006-03-07 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
CN102532120A (zh) * | 2002-08-23 | 2012-07-04 | 索隆-基特林癌症研究协会 | 埃坡霉素(epothilone),合成埃坡霉素的中间体,其类似物及其用途 |
US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
ES2439995T3 (es) | 2002-09-23 | 2014-01-27 | Bristol-Myers Squibb Company | Procedimientos de preparación, aislamiento y purificación de epotilona B |
WO2004032923A1 (fr) * | 2002-10-11 | 2004-04-22 | Dana-Farber Cancer Institute Inc | Derives epothilone pour le traitement du myelome multiple |
AU2003293796A1 (en) * | 2002-12-09 | 2004-06-30 | Novartis Ag | Microtubule stabilisers for treating stenosis in stents |
US20040146632A1 (en) * | 2003-01-23 | 2004-07-29 | Cristina Sayman | Effective multi-component penetrating and flavoring marinade |
JP2009513486A (ja) * | 2003-06-27 | 2009-04-02 | ノバルティス アクチエンゲゼルシャフト | エポチロンでの癌処置 |
CN1870995A (zh) * | 2003-09-02 | 2006-11-29 | 诺瓦提斯公司 | 使用埃坡霉素的癌症治疗 |
GB0405898D0 (en) | 2004-03-16 | 2004-04-21 | Novartis Ag | Organic compounds |
EP1640004A1 (fr) * | 2004-09-24 | 2006-03-29 | Schering Aktiengesellschaft | Utilisation des epothilones pour le traitement des metastases osseuses ou du cancer des os |
WO2006055740A1 (fr) * | 2004-11-18 | 2006-05-26 | Bristol-Myers Squibb Company | Bille a enrobage enterique comprenant de l’ixabepilone et son procede de preparation |
WO2006055742A1 (fr) * | 2004-11-18 | 2006-05-26 | Bristol-Myers Squibb Company | Bille enrobee de keratine comprenant de l'epothilone ou un analogue d'epothilone, ainsi que preparation et administration de cette bille |
JO2596B1 (en) * | 2004-11-30 | 2011-02-27 | نوفارتيس ايه جي | Compositions include epothelones and tyrosine protein kinase inhibitors and their pharmaceutical uses |
US20060121511A1 (en) | 2004-11-30 | 2006-06-08 | Hyerim Lee | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
DE102005008309A1 (de) * | 2005-02-17 | 2006-08-24 | Schering Ag | Pharmazeutische Mittel enthaltend fluoralkylhaltige Metallkomplexe und Epothilone |
MX2008012717A (es) * | 2006-04-05 | 2008-10-14 | Novartis Ag | Combinaciones de agentes terapeuticos para el tratamiento de cancer. |
CA2669696A1 (fr) * | 2006-11-15 | 2008-05-22 | Dana-Farber Cancer Institute, Inc. | Peptides maml stabilises et leurs utilisations |
US20100173718A1 (en) | 2007-06-20 | 2010-07-08 | Saluc Technologies S.A. | Convertible dining / billiard table |
EP2065054A1 (fr) | 2007-11-29 | 2009-06-03 | Bayer Schering Pharma Aktiengesellschaft | Combinaisons comprenant une prostaglandine et leurs utilisations |
EP2070521A1 (fr) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Nanoparticules à surface modifiée |
DE102007059752A1 (de) | 2007-12-10 | 2009-06-18 | Bayer Schering Pharma Aktiengesellschaft | Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone |
JP2012515172A (ja) | 2009-01-14 | 2012-07-05 | エルロン・セラピューティクス・インコーポレイテッド | ペプチド模倣大環状分子 |
EP2210584A1 (fr) | 2009-01-27 | 2010-07-28 | Bayer Schering Pharma Aktiengesellschaft | Composition polymère stable comprenant un copolymère séquencé d'épothilone et amphiphile |
WO2014116594A1 (fr) * | 2013-01-23 | 2014-07-31 | The University Of Toledo | Agents anticancéreux hautement sélectifs ciblant le cancer de poumon non à petites cellules et d'autres formes de cancer |
WO2017004548A1 (fr) | 2015-07-01 | 2017-01-05 | Aileron Therapeutics, Inc. | Macrocycles peptidomimétiques |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US253697A (en) * | 1882-02-14 | John halley and alexandee baee | ||
US127432A (en) * | 1872-06-04 | Improvement in tuckers for sewing-machines | ||
US87634A (en) * | 1869-03-09 | Improvement in grain-storehouses | ||
US203876A (en) * | 1878-05-21 | Improvement in piston water-meters | ||
US220295A (en) * | 1879-10-07 | Improvement in hinges | ||
US142990A (en) * | 1873-09-23 | Improvement in machines for burnishing the shanks of boots and shoes | ||
US203938A (en) * | 1878-05-21 | Improvement in wire fences | ||
US260098A (en) * | 1882-06-27 | Rolls for longitudinally slitting railroad-rails | ||
US34452A (en) * | 1862-02-18 | Improvement in railroad joints or chairs | ||
US176429A (en) * | 1876-04-25 | Improvement in nut-locks | ||
DE4138042C2 (de) * | 1991-11-19 | 1993-10-14 | Biotechnolog Forschung Gmbh | Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel |
ATE151767T1 (de) * | 1993-07-15 | 1997-05-15 | Pfizer | Amid-derivate von 16-gliedrige heterocyclen als antibiotische macrolide |
DE59610943D1 (de) * | 1995-11-17 | 2004-04-22 | Biotechnolog Forschung Gmbh | Epothilon-Derivate, ihre Herstellung und Verwendung |
US5969145A (en) * | 1996-08-30 | 1999-10-19 | Novartis Ag | Process for the production of epothilones and intermediate products within the process |
JP2001500851A (ja) | 1996-08-30 | 2001-01-23 | ノバルティス アクチエンゲゼルシャフト | エポシロンの製造法および製造過程中に得られる中間生産物 |
JP4274583B2 (ja) | 1996-11-18 | 2009-06-10 | ゲゼルシャフト・フュア・ビオテクノロギッシェ・フォルシュンク・ミット・ベシュレンクテル・ハフツング(ゲー・ベー・エフ) | エポチロンc,d,e及びf、製造と薬剤 |
US6515016B2 (en) | 1996-12-02 | 2003-02-04 | Angiotech Pharmaceuticals, Inc. | Composition and methods of paclitaxel for treating psoriasis |
US6204388B1 (en) | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
EP0977563B1 (fr) * | 1996-12-03 | 2005-10-12 | Sloan-Kettering Institute For Cancer Research | Synthese d'epothilones, intermediaires utilises dans leur synthese, analogues et utilisations de celles-ci |
US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
US6660758B1 (en) | 1996-12-13 | 2003-12-09 | The Scripps Research Institute | Epothilone analogs |
US6380394B1 (en) | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
DE19701758A1 (de) | 1997-01-20 | 1998-07-23 | Wessjohann Ludgar A Dr | Epothilone-Synthesebausteine |
DE19713970B4 (de) | 1997-04-04 | 2006-08-31 | R&D-Biopharmaceuticals Gmbh | Epothilone-Synthesebausteine II - Prenylderivate |
US6348551B1 (en) * | 1997-04-18 | 2002-02-19 | Studiengesellschaft Kohle Mbh | Selective olefin metathesis of bifunctional or polyfunctional substrates in compressed carbon dioxide as reaction medium |
DE19720312A1 (de) * | 1997-05-15 | 1998-11-19 | Hoechst Ag | Zubereitung mit erhöhter in vivo Verträglichkeit |
DE19821954A1 (de) | 1997-05-15 | 1998-11-19 | Biotechnolog Forschung Gmbh | Verfahren zur Herstellung eines Epothilon-Derivats |
DE19726627A1 (de) | 1997-06-17 | 1998-12-24 | Schering Ag | Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon |
US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
CA2299608A1 (fr) | 1997-08-09 | 1999-02-18 | Schering Aktiengesellschaft | Nouveaux derives d'epothilone, leur procede de fabrication et leur utilisation pharmaceutique |
SI1052974T1 (sl) | 1998-02-05 | 2009-10-31 | Novartis Ag | Farmacevtska formulacija, ki vsebuje epotilon |
US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
DE69927790T2 (de) | 1998-02-25 | 2006-07-20 | Sloan-Kettering Institute For Cancer Research | Synthese von epothilonen, ihren zwischenprodukten und analogen verbindungen |
FR2775187B1 (fr) * | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
US6302838B1 (en) * | 1998-02-25 | 2001-10-16 | Novartis Ag | Cancer treatment with epothilones |
GB9810659D0 (en) * | 1998-05-18 | 1998-07-15 | Ciba Geigy Ag | Organic compounds |
US6121029A (en) * | 1998-06-18 | 2000-09-19 | Novartis Ag | Genes for the biosynthesis of epothilones |
NZ508326A (en) | 1998-06-18 | 2003-10-31 | Novartis Ag | A polyketide synthase and non ribosomal peptide synthase genes, isolated from a myxobacterium, necessary for synthesis of epothiones A and B |
AU4775299A (en) | 1998-06-22 | 2000-01-10 | Nicolaou, Kyriacos Costa | Desmethyl epothilones |
WO2000000485A1 (fr) | 1998-06-30 | 2000-01-06 | Schering Aktiengesellschaft | Derives d'epothilone, leur procede de production, produits intermediaires et leur utilisation pharmaceutique |
DE19848306A1 (de) * | 1998-10-14 | 2000-04-20 | Schering Ag | Verfahren zur Herstellung von Epothilon B und Derivaten sowie Zwischenprodukte für dieses Verfahren |
US6303342B1 (en) | 1998-11-20 | 2001-10-16 | Kason Biosciences, Inc. | Recombinant methods and materials for producing epothilones C and D |
US6780620B1 (en) | 1998-12-23 | 2004-08-24 | Bristol-Myers Squibb Company | Microbial transformation method for the preparation of an epothilone |
DE60114865T2 (de) | 2000-04-28 | 2006-07-27 | Kosan Biosciences, Inc., Hayward | Heterologe herstellung von polyketiden |
WO2005085209A1 (fr) * | 2004-03-10 | 2005-09-15 | Kureha Corporation | Composé aminé basique et son usage |
-
1999
- 1999-02-16 FR FR9901903A patent/FR2775187B1/fr not_active Expired - Fee Related
- 1999-02-23 NZ NZ506187A patent/NZ506187A/en not_active IP Right Cessation
- 1999-02-23 EP EP99910257A patent/EP1056453B1/fr not_active Expired - Lifetime
- 1999-02-23 JP JP2000533117A patent/JP2002504511A/ja not_active Withdrawn
- 1999-02-23 CA CA002319752A patent/CA2319752A1/fr not_active Withdrawn
- 1999-02-23 WO PCT/EP1999/001147 patent/WO1999043320A1/fr active IP Right Grant
- 1999-02-23 AU AU29279/99A patent/AU755944B2/en not_active Ceased
- 1999-02-24 IT IT99MI000375A patent/ITMI990375A1/it unknown
- 1999-02-25 BE BE9900126A patent/BE1011980A5/fr not_active IP Right Cessation
-
2001
- 2001-08-09 US US09/925,119 patent/US6635666B2/en not_active Expired - Fee Related
-
2003
- 2003-08-01 US US10/633,114 patent/US20040024033A1/en not_active Abandoned
-
2005
- 2005-03-24 US US11/089,269 patent/US7091226B2/en not_active Expired - Fee Related
-
2006
- 2006-04-19 US US11/406,896 patent/US7875601B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
BE1011980A5 (fr) | 2000-03-07 |
EP1056453B1 (fr) | 2010-10-06 |
EP1056453A1 (fr) | 2000-12-06 |
JP2002504511A (ja) | 2002-02-12 |
US7091226B2 (en) | 2006-08-15 |
WO1999043320A1 (fr) | 1999-09-02 |
US20040024033A1 (en) | 2004-02-05 |
US20020028839A1 (en) | 2002-03-07 |
FR2775187A1 (fr) | 1999-08-27 |
US20060223867A1 (en) | 2006-10-05 |
NZ506187A (en) | 2003-11-28 |
US7875601B2 (en) | 2011-01-25 |
US20050165071A1 (en) | 2005-07-28 |
CA2319752A1 (fr) | 1999-09-02 |
US6635666B2 (en) | 2003-10-21 |
AU755944B2 (en) | 2003-01-02 |
ITMI990375A1 (it) | 1999-08-25 |
AU2927999A (en) | 1999-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR2775187B1 (fr) | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo | |
MA26790A1 (fr) | Composition dietetique ou pharmaceutique a l'usage pour la prevention ou le traitement de la hyper-oxalurie | |
FR2733684B1 (fr) | Utilisation de retinoides dans une composition cosmetique ou pour la fabrication d'une composition pharmaceutique | |
FR2780281B1 (fr) | Compositions comprenant des nanopigments d'oxydes de fer pour la coloration artificielle de la peau et utilisations | |
DZ2494A1 (fr) | Composition pharmaceutique d'oméprazole. | |
DE69918233D1 (de) | Polymilchsäure zusammensetzung und daraus hergestellter film | |
FR2765801B1 (fr) | Utilisation de monoesters d'arbutine comme agent depigmentant | |
BRPI9810519B1 (pt) | derivados de 4''-substituìdo-9-desoxo-9a-aza-9a-homoeritromicina a e composição farmacêutica compreendendo os mesmos. | |
MA26507A1 (fr) | Compositions pharmaceutiques d'aerosol | |
FR2708201B1 (fr) | Utilisation de dérivés d'acétamide pour la fabrication de médicaments. | |
FR2722681B1 (fr) | Calecon pour homme | |
FR2781148B1 (fr) | Composition cosmetique comprenant des pigments et un agent antitranspirant, utilisation d'une telle composition | |
FR2728783B1 (fr) | Prothese d'articulation metatarso-phalangienne totale du premier rayon du pied | |
EE200900049A (et) | Etinlstradiooli ja drospirenooni sisaldav farmatseutiline kompositsioon kasutamiseks rasestumisvastase vahendina | |
FR2714603B1 (fr) | Composition dermatologique et son utilisation pour la préparation d'un médicament. | |
MD283F1 (ro) | Compozitie de ingrediente pentru balsamul tonifiant "legenda" | |
FR2780427B1 (fr) | Poutre mixte bois-beton pour la construction et l'ouvrage d'art | |
FR2643643B1 (fr) | Compositions utilisables pour la preparation de membranes d'etancheite et membranes obtenues | |
FR2818907B1 (fr) | Utilisation de la brivudine pour la preparation d'une composition pharmaceutique | |
FR2750046B1 (fr) | Compositions sous forme d'un gel aqueux comprenant un ceramide ou un compose de type ceramide | |
FR2746012B1 (fr) | Utilisation de la tiamuline pour la preparation d'un medicament comme agent de reversion de la multichimioresistance cancereuse | |
FR2792833B1 (fr) | Utilisation de l'acide n-anisoyl-gamma-aminobutyrique ou de l'acide p-anisique pour la preparation d'une composition pharmaceutique | |
FR2722688B1 (fr) | Utilisation d'un extrait de la plante commiphoramukul comme agent pigmentant ou de culture de melanometique ou pharmaceutique, ou pour la culture des cytes; ou pour la fabrication d'une compostion cosmelanocytes | |
FR2722991B1 (fr) | Utilisation de la beta2-glycoproteine i sous au moins une de ses formes comme agent anti-infectueux et composition pharmaceutique corrrespondante | |
FR2800639B1 (fr) | Catalyseur bimetallique comprenant du fluor et son utilisation pour l'hydrogenation des composes aromatiques en presence de composes soufres |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ST | Notification of lapse |
Effective date: 20141031 |